Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota

• मुख्य लेखकों: Zhen Xiong Zhao (लेखक), Xiao Hui Tang (लेखक), Sheng Lu Jiang (लेखक), Jia Qian Pang (लेखक), Yu Bin Xu (लेखक), Dan Dan Yuan (लेखक), Ling Ling Zhang (लेखक), Hui Min Liu (लेखक), Qing Fan (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Hyperuricemic nephropathy (HN) is a common clinical complication of hyperuricemia. The pathogenesis of HN is directly related to urea metabolism in the gut microbiota. Febuxostat, a potent xanthine oxidase inhibitor, is the first-line drug used for the treatment of hyperuricemia. However, there have...